Additional Positive Trial Results Reported for Dysport in Cerebral Palsy with Lower Limb Spasticity
Ipsen Biopharmaceuticals reported additional results from an extended clinical trial evaluating the safety and effectiveness of Dysport (botulinum toxin type A) in children with lower limb spasticity due to cerebral palsy at this year’s meeting of the American Academy of Cerebral Palsy and Developmental Medicine Sept. 20-24 in Hollywood, Florida. The…